I2 FUND FAQS
The I2 FUND offers repayable growth capital to businesses (with less than 500 employees), commercializing innovative life science technology-based products, processes or services. The I2 FUND is a concrete step towards addressing the commercialization gap in the BC bioeconomy. Life sciences includes the biological aspects of industry challenges in the key economic sectors of Agriculture, Energy and Mining, Environment, Fisheries and Aquaculture, Forestry, and Human Health. The I2 Fund will also support digital health and other technologies that will further move the concept of precision medicine into clinical practice. The I2 funding is repayable and is allocated to promising technologies at the early stages of commercial development. The I2 FUND aims to provide risk capital that is concurrently matched by other public or private funding sources.
The I2 FUND is intended to be an ongoing initiative of GENOME BC.
A small- and medium-sized enterprise is defined by Industry Canada as a for-profit entity that has less than five hundred employees.
The I2 FUND is a GENOME BC initiative that is available to small-and medium-sized enterprises (SMEs) with operating facilities in BC.
The I2 FUND initiative aims to:
- Commercialize innovative life science and digital health technology-based products, processes, and services;
- Stimulate greater private sector investments in commercialization activities in the bioeconomy;
- Increase the number of jobs for highly qualified personnel in BC;
- Enable company growth.
GENOME BC will administer the Initiative.
Through the I2 FUND, GENOME BC is addressing a gap in private sector funding of the bioeconomy and the need to drive innovation, commercial success and economic prosperity in BC. More support is needed beyond the Research and Development phase to bring ideas through to commercially useful innovation. Attracting early-stage capital for life science technology commercialization has been identified as a key challenge for SMEs in BC. By helping businesses access financing and private investment, as well as supporting technology commercialization, we are harnessing the entrepreneurial spirit of this province, nurturing great ideas and strengthening BC’s economy.
The I2 FUND will help create an environment where businesses can thrive and compete in today's marketplace by exploiting life-science based technologies, ultimately strengthening BC’s economy.
Investing in technology commercialization is intended to encourage partnerships between SMEs and the investor community. While there is no funding to support angels or venture capital investors directly, investors working with businesses active in BC will be able to leverage their investments in companies that receive funding from the I2 FUND.
The I2 FUND’s repayable financing will be available to SMEs that meet the following mandatory criteria:
- SMEs (less than 500 employees) that are incorporated to do business in Canada and have operating facilities in British Columbia;
- Have a viable plan to commercialize (i.e., generate revenues from sales and/or licensing activities) an innovative, life science technology-driven, new or improved product, process or service within four years of initial I2 FUND disbursement;
- Ownership or contractually binding access to the intellectual property rights to carry out the proposed technology development and to commercially exploit the results of the project;
- Have provided a current business plan that details the investment opportunity and recent financial statements;
- Have identified, at the time of application, matching funding from all other sources, including government and non-government as well as existing cash resources (these sources of funding must represent at least 100 percent of the proposed I2 FUND financing and be secured by the closing date of the I2 funding).
The I2 FUND will target the following sectors where the exploitation of life science based technologies will strongly benefit the province of BC: Agriculture, Energy and Mining, Cleantech and Environment, Fisheries and Aquaculture, Forestry, and Human Health.
The I2 FUND launched in 2015 with an initial $6.8 million pool of capital. Eligible SMEs may request $100,000 to $1 million per company (and affiliates) to commercialize the development of their technology-based products, processes and services over a maximum four-year period. Only a limited number of exceptional SME’s are likely to receive a full $1 million in I2 FUND support.
It is expected that the requests for funding may exceed the amount of funding available. The total number of companies funded will depend on the amounts requested by the successful applicants.
Only applications demonstrating the highest merit that fit with I2 FUND objectives, will be considered for funding. Many good projects and businesses may not receive support from the I2 FUND.
All eligible applications will be evaluated on their ability to achieve the objectives of the I2 FUND and on their strengths in the areas of management, technology readiness, market potential, financial capacity and economic benefits.
Strong projects will demonstrate:
- A complete and viable business plan;
- Qualified, experienced and complete management team;
- Technology readiness for commercialization, strong value proposition and necessary IP;
- Market potential (i.e., strategic or supply chain partnerships in place, potential customers/investors identified, etc.);
- Financial capacity to execute (i.e., non-GENOME BC funding in place, existing revenues from other product lines, etc.) and ability to repay; and,
- Measurable economic benefits to BC.
I2 FUND supports activities in a variety of sectors; however, the funding is intended to support activities to validate commercial proof of concept and to commercially launch a product, process or service.
Examples of supported commercialization activities include, but are not limited to:
- Introduction of a new product, process or service to new or existing markets;
- Improvement of products, processes or services;
- Technology development/acceleration;
- Product certifications;
- Pilot projects (first user) and technology demonstration projects;
- Validation of market potential and end-user acceptance; and
- Support for marketing, human resources development, productivity, and process or quality improvement directly related to the commercialization of new opportunities.
The I2 FUND is providing repayable growth capital to SME’s where these proceeds are to be allocated to all necessary activities for the development and commercialization of promising life science-based technologies that have the potential to provide benefits to BC. The company must also commit to using BC based suppliers of goods and services for the technology development program where feasible and market competitive, and to ensure that all or substantially all of its employees or contractors who work on the technology development program are residents of BC if feasible.
GENOME BC reserves the right to make the final determination on the value of its support and to exclude expenditures deemed to be ineligible or outside the scope of the I2 FUND.
I2 FUND will not support costs that can be typically financed through conventional sources, such as land and buildings. Other non-eligible costs include: losses, amortization or depreciation of assets, fines, and penalties. Additionally, costs associated with certain activities, such as basic or applied research and lobbying, will not be supported.
No. Companies can submit multiple applications, however, there is a maximum funding limit of $1 million per recipient over a four-year period.
No. The eligibility requirements are that you must be incorporated at the time of application to the I2 FUND.
WHAT IF THE PARENT AND SUBSIDIARY COMBINED HAVE MORE THAN 500 FTES – WOULD THE SUBSIDIARY (WITH LESS THAN 500) BE ELIGIBLE?
No. If both the parent and subsidiary have more than 500 FTEs, then GENOME BC would not consider the subsidiary as eligible under I2 FUND. On a related note should there be a controlling interest by an investment firm, such as a venture capitalist, only the FTE count for the company applying will be considered for eligibility purposes and not the FTE count of the venture capitalist.
Yes. However, the company must establish tangible operating facilities in BC (with personnel) at the outset of their I2 Funding.
A company can use its existing cash or investments only if applied to new activities & costs – i.e. costs that are incurred after the I2 FUND start date.
WHAT DO YOU REQUIRE AS PROOF OR EVIDENCE OF IDENTIFIED MATCHING FUNDING AT THE TIME OF APPLICATION? IS A LETTER OF INTENT SUFFICIENT? ARE PROJECTED REVENUES FROM FUTURE SALES ACCEPTABLE?
Written proof, confirmed or conditional upon other sources of funding, will be considered acceptable. Examples of written proof include letters of intent, term sheets, funding agreements, or current bank statements detailing existing cash balances or the unused portion of lines of credit. These documents will be reviewed in greater detail as part of GENOME BC’s due diligence.
GENOME BC does not consider the following as sources of confirmed funding:
- Forecasted revenues from future activities;
- Accounts receivable;
- Commitments to raise equity;
- Commitments to obtain future bank financing; and
Forecast Scientific Research & Experimental Design (SR&ED) credits.
Any changes to funding sources would have to be considered on a case by case basis. Generally speaking as long as the SME continues to be capitalized sufficiently (meeting mandatory eligibility requirements) GENOME BC will continue to assess the investment opportunity.
IF A SME'S COMMERCIALIZATION PLAN IS TO UNDERTAKE A SERIES OF ACTIVITIES THAT WILL ENABLE IT TO LICENSE ITS PRODUCT TO A LARGE COMPANY, WITHIN FOUR YEARS, FOR A FEE (REVENUE) IS IT ELIGIBLE FOR THE I2 FUND?
Yes. Provided that the SME has the necessary IP rights to carry out the proposed technology development and it is feasible to commercially exploit the results within 4 years, the company would be eligible for financing from the I2 FUND. “Commercially exploit” includes out-licensing activities.
It is recommended that you consult the Canada Business Network http://www.canadabusiness.ca/eng/page/2752/ to access a variety of business plan tools from the BDC and Canada's major banks to ensure that your plan is complete and contains sufficient information to be assessed as a viable business plan. Another source for business plan tips and templates is the MARS Discovery District (incubator) website: https://www.marsdd.com/mars-library/create-a-business-plan-to-win-investors-template/
Generally, a business plan should include:
- A description of the business and new product, process, or service being commercialized (please include a description of intellectual property and freedom to operate);
- An analysis of the marketplace (including industry factors, competition, and customers);
- A detailed sales and marketing strategy;
- A description of the management team and corporate governance structure;
- Operating/execution plan for commercializing the new product;
- Forecasted income statements, cashflow for the duration of the development work and up to an additional 2 years (pro-forma statements).
Applicants are strongly encouraged to submit an Executive Summary (max. 5 pages) of their business plan highlighting:
- The company, team and BC-based activity
- The technology/service and value proposition
- The market opportunity
- The commercialization plan
- The financial requirements, prospective co-funders and risks involved
Submissions should be emailed to:
Director, Industry Innovation Programs
Only those applicants with the strongest applications will be invited to submit their full business plan for further consideration.
Applications are accepted at any time. However, the Board of Directors of GENOME BC will make the ultimate investment decisions. Board meetings and I2 FUND investment decisions are made approximately quarterly.
GENOME BC staff will not be reviewing nor assisting applicants to prepare their first submission of an Executive Summary prior to its submission. However, we will be available to discuss your company’s eligibility for I2 funding before your submission.
All applicants will receive an acknowledgement notification, confirming that their application has been received.
All proposals will be assessed and approved in five stages:
The first stage will consist of an initial assessment of the Executive Summary to determine if the SME’s business plan meets the mandatory criteria under the I2 FUND. During this stage, applicants will also be assessed to determine how strongly they align with the goals of the I2 FUND, whether they demonstrate a high likelihood of success and tangible benefits to BC and whether they will have non-GENOME BC matching funding secured by expected closing.
Assuming a positive assessment in Stage 1, GENOME BC will execute a confidentiality agreement and invite the company to submit a full business plan and/or other form of presentation to GENOME BC for the second stage of assessment.
Assuming support of GENOME BC in Stage 2, a formal due diligence process, is conducted to determine the likelihood of commercialization and clearly establishing a pathway to success. A confidential third party review of the company’s technology, IP and/or market will often be performed at this time.
If significant gaps are identified during the due diligence process, funds will not be advanced but GENOME BC will endeavour to point the company toward resources and partners that are able to help remedy the deficiencies.
If a company is successfully proceeding through Stage 3, then Genome BC will seek to negotiate and reach agreement on a term sheet detailing:
- Key financial terms
- Repayment terms
- Identification of commercialization milestones and tranche advancement requirements
- Closing conditions, co-funding and target dates
- Information rights
Upon completion of due diligence and negotiating the term sheet, the company will be asked to formally present to GENOME BC in the fifth and final stage of the review process. The Board of Directors of GENOME BC will make the ultimate investment decision. Board meetings and investment decisions are made approximately quarterly. GENOME BC will seek input from the I2 Advisory Council comprised of experienced businesspersons from the field of technology commercialization, entrepreneurs, and others in related fields that will provide strategic advice on the suite of investments under consideration by GENOME BC. Members of this Committee are required to sign a confidentiality agreement and a conflict of interest agreement with GENOME BC.
There are no fees associated with the application or assessment process. However, an applicant can expect that during the detailed due diligence period, they may be required to fund the costs of GENOME BC obtaining third party expert opinions – regardless of whether or not the I2 FUND makes an investment. GENOME BC will obtain prior approval from the applicant before incurring these expenses.
Assessment of the applications will be undertaken by GENOME BC. All submitted information will be kept in strict confidence. Confidential commercial information will not be shared without the applicant's consent. GENOME BC will execute a NDA prior to receipt of a full confidential business plan if requested.
WILL GENOME BC ASK FOR MISSING INFORMATION AND IF I AM NOT SUCCESSFUL, WILL I BE INFORMED WHY SO I CAN ADDRESS ANY WEAKNESSES IN MY APPLICATION FOR A FUTURE SUBMISSION?
GENOME BC staff may follow-up with clarification questions and may ask for the provision of new information. GENOME BC will try to provide individualized support for any applicant. However, applicants must clearly demonstrate the ability to bring innovative ideas from the later stages of research and development to a commercialized product, process or service.
If you are successful in obtaining I2 FUND funding for your company, GENOME BC will normally provide the repayable funding in an upfront disbursement at closing plus additional tranches triggered by the achievement of pre-determined milestones. Milestone events must be significant in nature for the development and commercialization of the technology. Milestone events must be described in a clear and objective fashion to avoid ambiguity whether they have been achieved or not. Ideally they are measureable.
Potential funding recipients are expected to have secured all non-GENOME BC matching financing (minimum 100%) before closing of the I2 FUND investment.
All successful applicants will sign a standard Loan Agreement with GENOME BC. The Agreement outlines the obligations of the funding recipient, including GENOME BC’s information rights which will require, at a minimum, quarterly reports including company progress reports, financial statements, budget variance reports and pro forma cash flows. In certain circumstances, GENOME BC may require Board Observer rights. GENOME BC retains visitation rights and the right to audit the loan recipient’s business during the loan repayment period and while any royalty payment obligations are outstanding.
The duration of the commercialization project may vary, ranging from a few months to multiple years; however, project plans must demonstrate the ability to commercialize the technology within four years of the first disbursement of I2 FUNDs (“Closing”).
Through this initiative GENOME BC will provide 'repayable funding’ – essentially an interest-bearing loan that will be secured with a General Security Agreement (“GSA”- see “WHAT IS THE LOAN SECURITY?”).
GENOME BC loans will be secured with a General Security Agreement granting an interest in all of the company’s and any subsidiary’s present and after acquired property. In the event of default, along with other remedies upon, default transfer of title and all rights to the technology, including intellectual property, by the company to GENOME BC.
I2 FUND loans are interest-bearing. Interest is calculated from the time of disbursement, compounded annually, and accrued until the repayment schedule is launched. Interest will be at a “below market” rate, usually the greater of: 5% or RBC Prime plus 3%. Interest penalties will be incurred if there are loan repayment defaults.
Funding recipients will be required to repay the I2 FUND loan principal and any accrued interest starting from the earliest of the following typical “Commercialization Triggers”:
- four years from the first disbursement of funds from the I2 FUND;
- the date that the commercialized technology achieves pre-negotiated revenue and/or sales volume targets;
- target revenues from licensing the technology;
- the company achieves a significant financial milestone such as an IPO or change of ownership control; or
- some other set date.
Recipients will be required to make quarterly repayments of the principal and accrued interest amortized over the two years following the occurrence of a Commercialization Trigger. Therefore, the funding recipient will have a maximum of six years to repay GENOME BC’s total principal and interest amount from its initial disbursement. There is no prepayment penalty. In fact, under certain circumstances, early repayment of the I2 funding will trigger up to a 50% reduction of the cap for I2 FUND Royalty obligations (please see “WHAT IS THE I2 FUND ROYALTY OBLIGATION?”)
A royalty obligation is part of the I2 FUND agreement. The royalty agreement is structured so that GENOME BC receives a low, single-digit annual royalty payment if the technology financed results in significant commercialization revenue. The royalty payments usually commence at the time of a Commercialization Trigger (see “HOW LONG DO FUNDING RECIPIENTS HAVE TO REPAY THE I2 FUND’S LOAN?”). The cumulative royalty payments are capped at 2X the amount of the I2 FUND loan principal. However, under certain circumstances, early repayment of the I2 FUND loan will trigger up to a 50% reduction of the cap for I2 FUND Royalty obligations.
There are no cash fees associated with the application process nor the execution of the I2 FUND loan transaction. However, the company will pay for all legal expenses incurred by the GENOME BC to document and execute the I2 FUND loan transaction.
At closing, GENOME BC will receive a Warrant - the right to purchase that number of shares of preferred or common stock of the company equal to 2.00% of the total I2 FUND loan divided by the Exercise Price. The Exercise Price will be equal to the per share price of the most recent equity round (common or preferred). The Warrant will have a ten year maturity and standard anti-dilution protection.
No, grants and subsidies are not provided under the I2 FUND Initiative. I2 FUND recipients will receive funding that they are responsible to repay (a repayable contribution).
GENOME BC expects that I2 Funding will be repaid. If funds are not repaid, GENOME BC will take appropriate measures to collect the amount owing from this loan default condition. The company (borrower) shall also be in default upon the occurrence of a material impairment of the prospect of repayment of the I2 FUND loan.
GENOME BC will not take a role in the operation of your business. Further, GENOME BC will not be taking any equity positions in businesses that receive funding under this program other than Warrants (see “ARE THERE ANY NON-CASH FEES TO CLOSE (SET UP) THE I2 FUND LOAN FACILITY?”).
There is no penalty for early repayment. Repayment of the loan shall not release the company from its Royalty obligations as set out in “WHAT IS THE I2FUND ROYALTY OBLIGATION?” However, under certain circumstances, early repayment of the I2 funding will trigger up to a 50% reduction of the cap for I2 FUND Royalty obligations.
No, loan guarantees will not be offered under the I2 FUND initiative, i.e., the intention is NOT to provide a guarantee to another lender.
Applicants will not be offered a line of credit under the I2 FUND initiative.
GENOME BC will not provide repayable financing based solely upon the assets you have in your business. We base our decisions on a variety of factors that will include: market potential, management strength, technology readiness and financial capacity.
WILL YOU PROVIDE FINANCING BASED UPON FUTURE PROJECTIONS FOR A NEWLY INVENTED TECHNOLOGICAL PRODUCT?
Yes, an applicant does not have to have existing revenues to be eligible to receive I2 FUND funding. It is required that the business be incorporated and have secured all other sources of non-GENOME BC matching funding at the time of disbursement.
It is recommended that you seek independent professional tax and accounting advice to assess and determine the full tax implications of your company being in receipt of an I2 FUND repayable loan.
If your company has an existing refundable tax credit receivable with the Scientific Research and Experimental Development (SR&ED) program and a valid track record for the receipt of past SR&ED tax credit claims, then 75% of the existing SR&ED receivable tax credit will be an eligible amount for the purposes of defining matching funding for I2 FUND investments. However, future SR&ED tax credits will not be considered matching funding. It is also recommended that you seek independent professional tax and accounting advice to assess and determine what costs and activities of your activities might be eligible for federal or provincial tax credits.
For additional I2 FUND information contact us directly at:
Director, Industry Innovation Programs
Click here for a printer friendly version.
Back to Industry Inovation Program.